It only takes natural outbreaks like the Ebola and Zika viruses to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.
Public-private partnerships for pandemic influenza and emerging infectious disease vaccine preparedness and response
The WHO blueprint: Nipah, MERS, LASSA, Zika, Chik
Modelling for dangerous pathogens and estimating vaccine efficacy